Double blind controlled trials of cholecystokinin octapeptide in neuroleptic-refractory schizophrenia.
A group of 14 schizophrenics who remained symptomatic after neuroleptic treatment received either 0.02 mcg/kg CCK-8 or saline placebo intravenously. Thereafter, 13 received the alternative infusion as a crossover treatment. A second group of 16 such patients received 0.04 mcg/kg CCK-8 or saline intravenously and, thereafter, 14 of these received the alternative infusion as a crossover treatment. Psychopathology was rated prior to, 2-3 h post, and on days 3, 5 and 7 after each infusion. Ratings consisted of the BPRS, the Abrams and Taylor Scale for Emotional Blunting, the Hamilton Anxiety Scale and a Schneiderian "Positive" symptom scale abstracted from the President State Examination. Parallel groups and cross over design analyses failed to show efficacy for CCK-8.
D014150:Antipsychotic Agents; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D010919:Placebos; D012559:Schizophrenia / Q000188:drug therapy*; D012844:Sincalide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D010919:Placebos; D012844:Sincalide